2024-11-26 - Analysis Report
## Vertex Pharmaceuticals Inc (VRTX) Stock Report

This report analyzes Vertex Pharmaceuticals Inc (VRTX), a biotechnology company focused on the discovery and development of innovative medicines for serious diseases.

**1. Performance vs. S&P 500 (VOO):**

VRTX has significantly outperformed the S&P 500 (VOO) over the analyzed period.  The cumulative return for VRTX is 166.65%, while VOO's is 127.58%. This represents a difference of 39.07%, placing it in the 66.43rd percentile of its historical performance relative to the S&P 500.  The provided data shows periods of both outperformance and underperformance relative to the benchmark, highlighting the inherent volatility of the biotech sector.

**Table 1: Alpha and Beta Analysis of VRTX**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 21.8% | 32.2% | -16.6% | 1.6 | 38.6 |
| 2016-2018  | 34.8% | 31.5% | 2.5% | 1.5 | 42.7 |
| 2017-2019  | 192.4% | 19.1% | 140.7% | 1.2 | 56.4 |
| 2018-2020  | 54.6% | 30.4% | 7.2% | 0.9 | 60.9 |
| 2019-2021  | 33.8% | 34.7% | -66.2% | 0.8 | 56.5 |
| 2020-2022  | 31.6% | 34.7% | 8.0% | 0.7 | 74.4 |
| 2021-2023  | 77.3% | 21.3% | 42.4% | 0.6 | 104.8 |
| 2022-2024  | 102.7% | 18.8% | 72.6% | 0.6 | 116.0 |


**2. Recent Price Movement:**

* **Closing Price:** 450.97 (Last Market: 457.71)
* **5-Day Moving Average:** 453.52
* **20-Day Moving Average:** 477.9
* **60-Day Moving Average:** 474.56

The price is currently below all three moving averages, suggesting a potential downward trend in the short term.  The last market price of 457.71 is only slightly higher than the closing price; there's no indication of a significant jump or drop.


**3. Technical Indicators:**

* **RSI (42.3):**  Approaching oversold territory (below 30), suggesting potential buying opportunities. However, it's not decisively oversold.
* **PPO (-1.11):** Negative value indicates bearish momentum.
* **20-Day Relative Divergence (-13.77):** Shows a recent short-term downtrend.
* **Expected Return (17.79%):**  This suggests a significant outperformance potential compared to the S&P 500 over the long term (2+ years) assuming current trends continue.


**4. Recent Financial Performance:**

**Table 2: Recent Earnings**

| Date       | EPS     | Revenue     |
|------------|---------|-------------|
| 2024-11-05 | 4.05    | $2.77 B     |
| 2024-08-02 | -13.92  | $2.65 B     |
| 2024-05-07 | 4.26    | $2.69 B     |
| 2023-11-07 | 4.01    | $2.48 B     |
| 2024-11-05 | 4.01    | $2.48 B     |


The most recent EPS (4.05) shows strong profitability. However, the August 2024 result (-13.92) shows significant volatility, requiring further investigation into the cause.  The repetition of the November 2023 data needs clarification.  Detailed analysis requires reviewing the company's financial reports and investor calls for further explanation.


**6. Financial Information:**

**Table 3: Revenue and Profitability**

| Quarter     | Revenue    | Profit Margin |
|-------------|------------|---------------|
| 2024-09-30  | $2.77B     | 85.84%        |
| 2024-06-30  | $2.65B     | 85.94%        |
| 2024-03-31  | $2.69B     | 87.27%        |
| 2023-12-31  | $2.52B     | 85.38%        |
| 2023-09-30  | $2.48B     | 87.17%        |

**Table 4: Capital and Profitability**

| Quarter     | Equity     | ROE          |
|-------------|------------|---------------|
| 2024-09-30  | $15.63B    | 6.69%         |
| 2024-06-30  | $14.77B    | -24.32%       |
| 2024-03-31  | $18.55B    | 5.93%         |
| 2023-12-31  | $17.58B    | 5.51%         |
| 2023-09-30  | $16.51B    | 6.27%         |


High and consistent profit margins demonstrate strong profitability.  However, the negative ROE in Q2 2024 needs further explanation.

**7. News and Recent Issues:**

*(This section requires accessing real-time news sources such as Shacknews and Finbold within the last two days.  Please provide the relevant news articles for a comprehensive analysis.)*  This section would include details on recent earnings announcements, analyst ratings, and any significant market events impacting VRTX.  It should cover recent market outlooks, analyst opinions and performance highlights, incorporating data from sources like FINBOLD.


**8. Overall Analysis:**

VRTX shows strong long-term growth potential, significantly outperforming the S&P 500.  However, recent financial results exhibit volatility, particularly the large negative EPS in August 2024, which necessitates thorough investigation. The relatively low RSI and negative PPO suggest a short-term bearish trend, but the long-term outlook remains positive based on historical performance and expected returns.  Careful consideration of the negative ROE and the explanation for the volatile EPS is crucial before making any investment decisions.  The analysis from the news and recent issues section (section 7) will further refine this overall assessment.


**9. Disclaimer:** This report is for informational purposes only and should not be considered investment advice.  Conduct thorough due diligence and consult with a financial advisor before making any investment decisions.  The analysis relies on the data provided and may not encompass all relevant factors.
